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DBackground: To evaluate trends and outcomes of descending thoracic aortic aneurysm (DTAA) repair in the
United States.
Methods: Adults undergoing DTAA repair between 1998 and 2008 were identified in the Nationwide Inpatient
Sample. To limit confounding, patients with connective tissue disorders, aortic dissection, or thoracoabdominal
aneurysms were excluded. Stratification was based on intact versus ruptured DTAA and open versus endovas-
cular approach. Standardized annual rates of repair were calculated based on US Census Bureau population
estimates. Logistic regression analysis incorporating multiple patient, operative, and hospital variables was
used for risk adjustment.
Results: A total of 20,568 DTAA patients (intact, 17,780; ruptured, 2788) underwent repair (open, 15,265;
endovascular, 5303). Patients undergoing repair in the more recent era had higher comorbidity burdens than
those undergoing repair in the earlier era. Despite this, annual rates of repair for both intact and ruptured DTAAs
increased significantly during the study period (intact, 2.2-10.6 per 1 million; ruptured, 0.8-1.3 per 1 million;
P< .05), primarily because of increases in rates of endovascular repair in recent years. Operative mortality
decreased from 10.3% to 3.1% for repairs of intact DTAAs (P<.001) and from 52.6% to 23.4% for ruptured
DTAAs (P ¼ .002). Endovascular repair was associated with reduced risk-adjusted mortality for both intact
(odds ratio, 0.31; P<.001) and ruptured (odds ratio, 0.41; P ¼ .001) DTAAs.
Conclusions: Although patients undergoing DTAA repair in the modern era have a higher comorbidity burden,
rates of repair have increased and operativemortality has decreased, in part because of the increasing adoption of
endovascular approaches. (J Thorac Cardiovasc Surg 2014;147:1855-60)Thoracic aortic aneurysms have an estimated incidence of 6
to 10 per 100,000 person-years, ofwhich 40% are composed
of descending thoracic aortic aneurysms (DTAAs).1-3 As
with other aortic pathologic conditions, the management
of DTAA has changed significantly during the past several
years. For instance, the evolution of multidetector computed
tomography has resulted in more rapid image acquisition
and improved 3-dimensional reconstruction. This has led to
better evaluation of the complex anatomic features in
DTAA, including aortic tortuosity, relation of the aneurysm
to branch vessels, and presence of dissection.4 Operative
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The Journal of Thoracic and Carorgan-specific protective strategies, such as cerebrospinal
fluid drainage, reimplantation of intercostal arteries, regional
hypothermia, use of evoked-potential monitoring, and distal
aortic perfusion, to reduce the risk of spinal cord ischemia.5-7
The introduction of thoracic endovascular aortic repair
(TEVAR) is perhaps the most notable change in the manage-
ment of DTAA. TEVAR is particularly attractive given the
frequently significant comorbidity burden of these patients.
The aim of this study was to evaluate trends and outcomes of
DTAA repair in theUnited States during the past several years.METHODS
Data Source
The Nationwide Inpatient Sample (NIS) was used for this study. This
registry was developed by the Agency for Healthcare Research and Quality,
and contains inpatient data on more than 8 million patient visits per year,
with more than 1050 participating hospitals.8 After weighting, this reflects
approximately 95% of hospital discharges within the United States. The
data provided by the NIS are deidentified. The Johns Hopkins Institutional
Review Board, therefore, granted this study exempt status.
Study Population
Adults (>17 years) undergoing DTAA repair between January 1998 and
December 2008 were identified in the NIS database. International Classi-
fication of Diseases, Ninth Revision (ICD-9), codes were used to identify
the study population. Intact thoracic aneurysms were identified with the
International Classification of Diseases, Ninth Revision (ICD-9), diagnosisdiovascular Surgery c Volume 147, Number 6 1855
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COPD ¼ chronic obstructive pulmonary disease
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Dcode 441.2, and ruptured thoracic aneurysms were identified with the code
441.1. Procedure codes 38.45 and 39.73 were used to identify open and en-
dovascular repairs, respectively. Patients with procedure codes for both
open and endovascular DTAA repair were excluded from the study. To
isolate DTAAs, patients with aortic dissections (diagnosis codes 441.00-
441.03), thoracoabdominal aneurysms (diagnosis codes 441.3-441.9 or
procedure code 38.44 or 39.71), abdominal aortic aneurysms (diagnosis
code 441.3 or 441.4 or procedure code 38.46 or 39.71), or connective tissue
disorders (diagnosis codes 446.0-446.7 and 759.82) were excluded from
the analysis. In addition, patients undergoing cardiac valve or coronary
bypass surgery (procedure codes 35.11, 35.12, 35.14, 35.21, 35.22,
35.23, 35.24, 35.27, 35.28, and 36.10-36.19), aortic to subclavian or aortic
to carotid bypass (39.22), intrathoracic bypass (39.23), or hypothermic cir-
culatory arrest (procedure code 39.62) were excluded.
Data Analysis
Stratificationwas based on intact versus ruptured DTAA repair and open
versus endovascular approach. Baseline characteristics were initially eval-
uated for the study cohort. These included patient-specific variables, such
as age, sex, and comorbidities, including prior myocardial infarction,
congestive heart failure, cerebrovascular disease, chronic obstructive pul-
monary disease (COPD), diabetes mellitus, liver disease, and chronic renal
insufficiency. The Charlson comorbidity index, which is a validated mea-
sure of overall comorbidity burden, was also calculated for each patient.9
We evaluated hospital-specific variables, including teaching status, rural
versus urban location, and large size designation, as determined by number
of beds. These baseline characteristics were compared between patients
undergoing repair in the pre-TEVAR (1998-2004) versus TEVAR (2005-
2008) era.
Annual rates of repair were also calculated for both intact and ruptured
cases. These were based on population estimates as provided by the US
Census Bureau.10 In addition to evaluating overall rates of repair, we
also examined rates of open versus endovascular repair. Annual unadjusted
operative mortality rates were then calculated for the intact and ruptured
cohorts. Linear regression was used to determine the statistical significance
of the trend in operative mortality during the study time period.
Finally, multivariable logistic regression models were constructed to
identify predictors of operative mortality. Separate models were created
for intact and ruptured DTAA repairs. Variables included in the model
were age, sex, comorbidities, teaching status of hospital, hospital location,
hospital size, era, and operative approach.
Survey statistics were used for statistical comparisons. This included the
adjusted Wald test for continuous data and a design-based Pearson c2 test
for categorical data. Odds ratios from the multivariable model were
presented with 95% confidence intervals. All statistical analyses were per-




A total of 20,568 patients underwent DTAA repair during
the study period. The mean age for the overall cohort was
64.7  14.0 years. There were 5594 (27.2%) patients
aged 75 years or older. Most patients in the study were1856 The Journal of Thoracic and Cardiovascular Surmale (58.2%; n ¼ 11,971). The most common comorbidity
wasCOPD (24.7%; n¼ 5080), followed by congestive heart
failure (11.1%; n ¼ 2283) and cerebrovascular disease
(10.9%; n ¼ 2242). Most repairs were performed at
large (81.6%; n ¼ 16,783) teaching hospitals (78.9%;
n¼ 16,228) located in an urban setting (98.7%; n¼ 20,301).
Trends in Baseline Characteristics Over Time
Several significant differences were noted when
comparing characteristics of patients undergoing repair of
intact DTAA in the pre-TEVAR versus TEVAR era. Patients
undergoing repair of intact DTAAs in the TEVAR era were
older and had more comorbidities (Table 1). More specif-
ically, those in the TEVAR era had higher rates of prior
myocardial infarction, diabetes mellitus, and chronic renal
insufficiency, as well as a higher overall Charlson comor-
bidity index. There was also a trend toward a higher rate
of COPD in the TEVAR era. Hospital characteristics were
comparable between eras.
Similarly, patients undergoing repair of ruptured DTAAs
in the TEVAR era had a higher overall comorbidity burden,
as measured by the Charlson score, compared with those
undergoing repair of ruptured DTAAs in the pre-TEVAR
era (Table 2). Chronic renal insufficiency was approxi-
mately 2-fold more common in the TEVAR era. Similar
to repairs of intact DTAAs, hospital characteristics were
similar between eras for the repairs of ruptured DTAAs.
Rates of Repair
The overall repair rates of intact DTAA increased signif-
icantly during the study period, from2.2 to 10.6 per 1million
in 1998 and 2008, respectively (r¼ 0.89,P<.001) (Figure 1,
A). Although open repair rates for intact DTAAs remained
relatively stagnant during the past few years of the study
period (open, from 3.8 in 2005 to 4.4 in 2008 per 1 million),
the introduction of endovascular approaches in 2005 and
their increasing use thereafter (TEVAR, from 1.0 in 2005
to 6.2 in 2008 per 1 million) resulted in increased overall
rates.
The repair rates of ruptured DTAA also increased signif-
icantly during the study period, although to a less significant
degree as that observed with the intact cohort, from 0.8 to
1.3 per 1 million (r ¼ 0.59, P<.001) (Figure 1, B). Similar
to the intact group, open repair rates for ruptured DTAAs
were relatively stagnant in recent years (open, from 0.6 in
2005 to 0.6 in 2008 per 1 million), with the increasing adop-
tion of endovascular therapy (TEVAR, from 0.1 in 2005 to
0.7 in 2008 per 1 million) driving the increase in overall
repair rates.
Operative Mortality
Unadjusted operative mortality rates were significantly
lower with TEVAR versus open surgery for both the intact
(TEVAR vs open, 2.7% vs 6.3%; P<.001) and rupturedgery c June 2014
TABLE 1. Study population characteristics of the cohort undergoing repair for intact DTAAs
Variables Repair of intact DTAA (n ¼ 17,780)
Era
1998-2004 (n ¼ 8428) 2005-2008 (n ¼ 9352) P value
Age, y 64.1  14.1 62.4  13.6 65.6  14.3 <.001
Female sex 7361 (41) 3540 (42) 3821 (41) .52
Charlson comorbidity index 1.02  1.17 0.83  0.97 1.18  1.32 <.001
Comorbidities
Myocardial infarction 1034 (6) 402 (5) 632 (7) .03
Congestive heart failure 1866 (10) 818 (10) 1048 (11) .21
Cerebrovascular disease 1776 (10) 856 (10) 920 (10) .76
COPD 4384 (25) 1938 (23) 2446 (26) .07
Diabetes mellitus 1789 (10) 659 (8) 1130 (12) <.001
Liver disease 97 (0.5) 37 (0.4) 60 (0.6) .41
Chronic renal insufficiency 1185 (7) 249 (3) 936 (10) <.001
Teaching hospital 13,986 (79) 6777 (80) 7209 (77) .51
Urban hospital location 17,529 (99) 8329 (99) 9200 (98) .59
Large hospital 14,611 (82) 7129 (85) 7482 (80) .28
Data are given as mean  SD or number (%). DTAA, Descending thoracic aortic aneurysm; COPD, chronic obstructive pulmonary disease.
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D(TEVAR vs open, 21.5% vs 36.6%; P< .001) cohorts.
When grouped together, overall unadjusted operative
mortality rates decreased significantly during the study
period for repairs of both intact and ruptured DTAAs. For
repairs of intact DTAAs, operative mortality decreased
from 10.3% in 1998 to 3.1% in 2008 (P < .001)
(Figure 2, A). For repairs of ruptured DTAAs, operative
mortality decreased from 52.6% in 1998 to 23.4% in
2008 (P ¼ .002) (Figure 2, B).
Predictors of Operative Mortality
There were several significant predictors of operative
mortality identified in the intact DTAA cohort. These
included increasing age, with each additional decade of
age being associated with an incremental 50% increase in
operative mortality (Table 3). Cerebrovascular and liver dis-
eases were each associated with a more than 4-fold increaseTABLE 2. Study population characteristics of the cohort undergoing repa
Variables Repair of ruptured DTAAs (n ¼ 2788)
Age, y 68.6  13.4
Female sex 1228 (44)
Charlson comorbidity index 2.14  1.26
Comorbidities
Myocardial infarction 253 (9)
Congestive heart failure 428 (15)
Cerebrovascular disease 466 (17)
COPD 695 (25)
Diabetes mellitus 227 (8)
Liver disease 11 (0.4)
Chronic renal insufficiency 320 (11)
Teaching hospital 2241 (80)
Urban hospital location 2777 (99)
Large hospital 2173 (78)
Data are given as mean  SD or number (%). DTAA, Descending thoracic aortic aneurys
The Journal of Thoracic and Carin operative mortality risk. Prior myocardial infarction and
chronic renal insufficiency each also exerted a nearly 2-fold
increase in operative mortality risk. Those repaired with an
open approach were roughly 3 times more likely to die than
those undergoing TEVAR. Earlier era was also a significant
risk factor for operative mortality.
Increasing age increased the risk of operative mortality in
the ruptured cohort as well (Table 4). Each decade increase
in age was associated with a 30% increase in mortality risk.
Comorbidities and teaching characteristics did not affect
mortality in the ruptured cases. An open approach was asso-
ciated with a 2.7-fold increase in mortality risk compared
with TEVAR in ruptured DTAAs. The effect of earlier era
on mortality risk observed in unadjusted analysis no longer
persisted in the risk-adjusted model.
Because of the greater number of patients in the intact
DTAA cohort, the multivariable model for that particularir of ruptured DTAAs
Era
1998-2004 (n ¼ 1596) 2005-2008 (n ¼ 1192) P value
68.0  13.1 69.4  13.8 .23
660 (41) 568 (48) .17
2.01  1.14 2.32  1.40 .007
140 (9) 113 (9) .82
248 (16) 180 (15) .90
267 (17) 199 (17) .98
399 (25) 296 (25) .98
107 (7) 120 (10) .17
0 (0) 11 (0.9) .09
136 (9) 184 (15) .02
1300 (81) 941 (79) .60
1590 (99) 1187 (99) .95
1224 (77) 949 (80) .57
m; COPD, chronic obstructive pulmonary disease.
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FIGURE 1. Standardized annual rates of open and endovascular repair of
intact (A) and ruptured (B) descending thoracic aortic aneurysms.
FIGURE 2. Annual unadjusted operative mortality rates for repair of
intact (A) and ruptured (B) descending thoracic aortic aneurysms (DTAAs).
In 2005, there were only 16 endovascular repairs of ruptured DTAAs.
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Danalysis had higher predictive power. Moreover, the c-index
for the model for repair of intact DTAAs was 0.80. This was
higher than the c-index for the multivariable model for
repair of ruptured DTAAs, which was 0.66.
DISCUSSION
Study Findings
In this study, we evaluated trends and outcomes of DTAA
repair in the United States during the past decade. There
were several important findings from this population-
based analysis. Foremost, standardized rates of repair had
significantly increased over time for both intact and
ruptured DTAAs. Given that the rates of open repair were
relatively constant in the latter portion of the study period,
the increasing adoption of TEVAR, starting in 2005, is the
most likely driving factor for these increased rates of repair.
Because patients in more recent years had higher comorbid-
ity burdens, this suggests that TEVAR has helped augment
the overall pool of DTAA repairs, in part by allowing sicker
patients to undergo surgical intervention.
Furthermore, we found that operative mortality rates
decreased significantly during the study period for repairs
of both intact and ruptured DTAAs. Again, these findings
occurred despite a higher comorbidity burden in patients.
In multivariable analysis, we found that increasing age
was a significant predictor of operative mortality for repairs1858 The Journal of Thoracic and Cardiovascular Surof both intact and ruptured DTAAs. Older age is a well-
known predictor of adverse outcomes after major aortic pro-
cedures. A statewide analysis of thoracoabdominal aortic
aneurysm repairs demonstrated steep increases in 1-year
mortality with increasing age, from 18% for 50- to 59-
year-old patients to 40% for 80- to 89-year-old patients.11
A similar multicenter analysis performed for abdominal
aortic aneurysms showed parallel results, with 1-year mor-
tality ranging from 2.9% in those aged 51 to 60 years to
15% for those aged 81 to 90 years.12 Finally, in multivari-
able analysis, we found that, after accounting for patient and
hospital characteristics, open surgical repair was associated
with a significant increase in mortality risk compared with
TEVAR for both intact and ruptured DTAAs.Prior Studies
Indeed, open repair of DTAA has been associated with
significant morbidity and mortality in prior series. In a
single-institution review of 387 patients, the in-hospital
mortality rate was 4.4%, with a 30-day mortality of
2.8%.13 In another single-institution study of 300 patients,
the 30-day mortality was 8%.7 An earlier study of 366 pa-
tients demonstrated an in-hospital mortality rate of 12%
that decreased to 9.9% if ruptured aneurysms were
excluded.14 These data generally coincide with our currentgery c June 2014
TABLE 3. Multivariable analysis for inpatient mortality after repair
of intact DTAAs
Covariates Odds ratio (95% CI) P value
Age (increasing, per year) 1.05 (1.03-1.07) <.001
Female sex 0.96 (0.66-1.39) .81
Comorbidities
Myocardial infarction 1.90 (1.08-3.36) .03
Congestive heart failure 1.03 (0.62-1.71) .91
Cerebrovascular disease 4.92 (3.40-7.11) <.001
COPD 1.22 (0.87-1.72) .26
Diabetes mellitus 0.71 (0.38-1.33) .29
Liver disease 4.22 (1.35-13.2) .01
Chronic renal insufficiency 1.92 (1.46-2.53) <.001
Nonteaching hospital 1.06 (0.70-1.62) .78
Rural hospital 1.47 (0.40-5.38) .56
Small or medium hospital 1.29 (0.86-1.96) .22
Early era 2.12 (1.28-3.50) .003
Open approach 2.94 (1.67-5.16) <.001
DTAA, Descending thoracic aortic aneurysm; CI, confidence interval; COPD, chronic
obstructive pulmonary disease.
TABLE 4. Multivariable analysis for inpatient mortality after repair
of ruptured DTAA
Covariates Odds ratio (95% CI) P value
Age (increasing, per year) 1.03 (1.01-1.05) .001
Female sex 0.80 (0.51-1.25) .33
Comorbidities
Myocardial infarction 1.38 (0.72-2.65) .33
Congestive heart failure 0.94 (0.55-1.62) .83
Cerebrovascular disease 1.33 (0.80-2.19) .27
COPD 1.27 (0.83-1.94) .26
Diabetes mellitus 1.40 (0.70-2.81) .34
Liver disease 3.35 (0.39-29.0) .27
Chronic renal insufficiency 1.31 (0.94-1.83) .11
Nonteaching hospital 0.92 (0.56-1.53) .75
Rural hospital 1.88 (0.02-163.2) .78
Small or medium hospital 1.17 (0.72-1.88) .53
Early era 1.00 (0.63-1.61) .99
Open approach 2.72 (1.47-5.02) .001
DTAA, Descending thoracic aortic aneurysm;CI, confidence interval; COPD, chronic
obstructive pulmonary disease.
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Danalysis, in which the overall operative mortality rates for
open repair of intact and ruptured DTAAs were 6.3% and
36.6%, respectively.
Data for TEVAR in the management of DTAA have been
promising. A single-institution analysis of 224 patients
undergoing TEVAR for DTAA demonstrated a 30-day
mortality of 3% and a 1-year mortality of 15%.15 An
analysis comparing TEVAR with open surgical repair at a
single center demonstrated reduced 30-day (5.7% vs
25%) and 1-year (19% vs 42%) mortality rates with
TEVAR.16
Multicenter trial data of 142 patients undergoing TEVAR
demonstrated successful implantation of the device in 98%,
with a 30-day mortality of 1.5%.17 A comparative study of
TEVAR trial patients and an open surgical control cohort
demonstrated reduced perioperative mortality (2.1% vs
11.7%), with lower rates of postoperative spinal cord
ischemia, respiratory tract failure, and renal insufficiency
in the TEVAR group.18 In The Valiant Thoracic Stent Graft
System Clinical Study (VALOR II) trial, 160 patients un-
derwent TEVAR for DTAA, with successful deployment
in 96.3% and a perioperative mortality rate of 3.1%.19
In addition to single-institutional and trial data, there
have been prior analyses of nationwide outcomes, although
none have examined repairs for both intact and ruptured
DTAAs for all adult ages during an 11-year period, as our
study did. In 1 analysis of NIS data between 2006 and
2007, TEVAR was associated with improved inpatient
outcomes for intact DTAA repair.20 Another nationwide
analysis of ruptured DTAA repair between 2006 and 2008
by the same group demonstrated equivalent outcomes
between TEVAR and open repair.21 The discrepancy
between the latter study and our study regarding the
mortality benefit of TEVAR for ruptured DTAA may beThe Journal of Thoracic and Carbecause our analysis had more than 3-fold more patients
and was adequately powered to detect a difference.
Study Implications
Our study adds to the literature on DTAA repair by
providing a decade-long analysis of ‘‘real-world’’ data.
Moreover, the NIS registry is a better reflection of real-
world clinical practices and outcomes, compared with
clinical registries or trials in which participation is voluntary
and reporting biases are often present. Our analysis
demonstrates that the findings from prior single-institution
studies and trial data are generally mirrored on a national
level, where TEVAR is associated with reduced risk-
adjusted operative mortality for repair of both intact and
ruptured DTAAs. Perhaps most important, it demonstrates
that more patients are able to undergo surgical intervention
for this disease entity and that national outcomes have
improved.
Despite these collective data demonstrating the short-
term advantages of an endovascular approach, the longer-
term benefits of TEVAR remain to be established. Indeed,
prior analyses of Medicare data have suggested otherwise.
A study of Medicare patients undergoing DTAA repair
from 2004 to 2007 demonstrated significant reductions
in perioperative mortality with TEVAR, but equivalent
5-year survival between approaches.22 Another analysis
of Medicare data demonstrated lower perioperative
mortality but worse 1- and 5-year survival with TEVAR
compared with open DTAA repair.23 It is certainly
plausible that the relative benefits of TEVAR lessen as
the time from surgery lengthens, especially given the
higher comorbidity burdens of the patients in this cohort.
Close continued surveillance is a key component of any
endovascular program because some patients may becomediovascular Surgery c Volume 147, Number 6 1859
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Dlost to follow-up and risk rupture from a late endoleak. In
addition, open surgical repair will remain an important
component of DTAA treatment because some aneurysms
are not amenable to endovascular approaches and some in-
stitutions or providers do not have the resources or training
to perform TEVAR.
Study Limitations
A principal limitation of our analysis is the lack of radio-
logic data within the NIS registry. Accordingly, aneurysmal
features that would be expected to affect outcomes, such as
size, rate of progression, relation to branch vessels, and
overall amenability to an endovascular approach, were not
available. Other variables, including surgeon expertise
and training and institutional resources, were not included
in the analysis. Finally, our analysis was limited to inpatient
outcomes, but longitudinal data, including long-term
survival, functional recovery, and rates of endoleak for
TEVAR, are additional end points that are relevant.
CONCLUSIONS
This population-based analysis of more than 20,000
DTAA repairs in the United States provides encouraging
data, demonstrating that operative outcomes have improved
during the past decade. In addition, the increasing use of
TEVAR has allowed sicker patients to undergo surgery
for DTAA, and has contributed to the overall increase in
repair rates observed for both intact and ruptured cases.
These data collectively support broader implementation
and enablement of TEVAR for the management of DTAA.
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